Europe Bioreactors Market Forecast to 2027 - COVID-19 Impact - Regional Analysis and Market Forecasts by Cell, Molecule, Technology and End User

The European bioreactors market is expected to reach US$ 1,512.45 Mn by 2027 from US$ 885.26 Mn in 2019. The market is estimated to grow at a CAGR of 7.0% from 2020 to 2027.The growth of The European bioreactors market is primarily attributed to the rapidly growing biopharmaceutical and biotechnology industries and increasing adoption of single-use bioreactors. However, stringent regulatory frameworks in different countries hinder the market growth in the region. Additionally, technological advancements in bioreactors and rising demand for personalized medicines are likely to boost the growth of The European bioreactors market during the forecast period.

A bioreactor is equipment or system engineered to provide biologically active environment for the production of various medical and pharmaceutical compounds. The vessel is used to carry out a chemical process, which involves organisms or biochemically active substances derived from such organisms. This process can either be aerobic or anaerobic. Bioreactors are commonly cylindrical in shape, ranging in capacities from liters to cubic meters, and are generally made of stainless steel. Bioreactors provide a controllable environment, in terms of pH, temperature, nutrient supply, and shear stress. These equipment are used in a variety of applications, such as production of biopharmaceuticals and tissue engineering products.

The pharmaceuticals industry has been growing at an unprecedented pace in the recent years, and with this the biopharmaceuticals market is also expanding. With the aging population and rising healthcare standards, the demand for pharmaceutical products has been escalating in European countries. The strong demand for drugs and pharmaceuticals has been driving the growth of The European bioreactors market. Moreover, increasing approvals in gene and cell therapies are favoring the growth of the bioreactors market in Europe. The approved gene therapies are Glybera-used to treat Lipoprotein Lipase Deficiency, and Strimvelis- treating ADA-Severe Combined Immunodeficiency. The factors mentioned above are increasing the demand for the large-scale production of various therapeutic substances, thereby encouraging companies to deploy more bioreactors in their production facilities.

Europe has been massively hit by the recent COVID-19 pandemic that has affected many of its countries on a large scale. Italy, Germany, Spain, the UK, and France, among others, are continually witnessing rise in number of positive cases every day. The dependency of European country on China for raw materials is hampering the pharmaceutical supply in the region. These factors are majorly anticipated to hamper the growth of the market in Europe. According to data published in a newsletter in March 2020, Majority of the European pharmaceutical companies have manufacturing facilities located in India, while they procure ~70.0% of the raw ingredients from China. Thus, the lockdown and industrial shutdown in different countries are likely to hamper whole supply chain, which will ultimately hamper the growth of the bioreactors market inEurope.

In 2019, the mammalian cells segment accounted for the largest share of the Europe bioreactors market. However, the yeast cells segment is estimated to report the highest CAGR during the forecast period. Yeasts are cost-effective, fast-growing, and can be used for high-density cell cultures in bioreactors. Moreover rapid growth rate, easy genetic manipulation, complete genome sequence knowledge, cost-effective growth medium requirements, and post-translational modifications flexibility make yeasts perfect hosts for recombinant protein expression.

A few of the significant secondary sources referred to while preparing the report on the Europe bioreactors market report include the World Health Organization (WHO) andEuropean Medicines Agency (EMA).

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in The European Bioreactors Market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in The European Bioreactors market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.